The North America contrast enhanced ultrasound market is set to propel with a 5.36% CAGR by 2030, and is expected to be valued at $884.85 million during the assessment period, 2022-2030.

In North America, contrast-enhanced ultrasound is largely used in abdominal and cardiac imaging. With recent approval to characterize liver lesions, contrast-enhanced ultrasound imaging is gaining more traction. Also, rising cases of numerous health conditions and chronic illnesses and the urgency for early detection and diagnosis will further propel the studied market towards growth. Moreover, a rising number of training and education programs for radiologists and sonographers regarding diagnostic & therapeutic use of contrast-enhanced ultrasound is expected to boost the region’s growth over the forecast period.

To know more about this report, request a free sample copy

The North America contrast enhanced ultrasound market growth evaluation entails the study of the United States and Canada. The United States contrast-enhanced ultrasound market is anticipated to grow over the forecast year due to increasing healthcare providers’ awareness of ultrasound devices’ safety and diagnostic effectiveness. The nation has well-established medical codes, payment procedures, and coverage regulations for ultrasound services in hospitals, clinics, and ambulatory centers.

Additionally, general practitioners and family doctors are reimbursed for using ultrasounds in their offices. The number of ultrasound procedures has increased in the United States. The prevalence of inflammatory bowel disorders (IBD) and cardiovascular illness is predicted to increase, increasing the demand for contrast-enhanced ultrasonography nationwide. According to the America College of Cardiology, 840,768 deaths occurred in the United States due to cardiovascular disorders in 2016, while the country also had a high age-standardized prevalence rate of 464·5 every 100,000 for IBD in 2017.

The North America contrast enhanced ultrasound market analysis includes segmentation by end-user, product, and type. Market by product covers equipment and contrast agents.

To promote product usability and enhance the diagnostic experience of the machine operator, ultrasound system manufacturers are increasingly offering comprehensive solutions for ultrasound imaging in a single system. As it is being employed in all upcoming ultrasound technologies, contrast-enhanced ultrasound imaging is an emerging technique that has lately received approval for several new applications. The development of ultrasound modalities and agents specifically suited for contrast imaging by pharmaceutical firms, academic institutions, and ultrasound manufacturers is also anticipated to fuel segment growth throughout the forecast period.

Some of the leading players in the North America contrast enhanced ultrasound market include Lantheus Medical Imaging Inc, Bracco Diagnostic Inc, etc.

Lantheus Medical Imaging Inc is a subsidiary of Lantheus Holdings Inc and develops, manufactures, and commercializes diagnostic imaging agents and products for diagnosing conditions that affect the heart, brain, lungs, and other organs using echocardiography and nuclear imaging. The company’s major products include ultrasound contrast agents, inhalable and injectable radiopharmaceutical imaging agents, and technetium-based generators. Its products diagnose coronary artery disease, stroke, congestive heart failure, cancerous tumors and other diseases.

Furthermore, Lantheus Medical Imaging has a strong brand presence and has been operating in the US healthcare market for over 60 years. Lantheus’s established presence helps it attract and serve a diverse customer base and build customer confidence in its product portfolio. The company offers its products to radiologists, internal medicine physicians, cardiologists, nuclear physicians, sonographers, and technologists. The company is headquartered in North Billerica, Massachusetts, United States.

DEFINITY from Lantheus Medical Imaging is a cardiovascular ultrasound enhancement agent used as an injectable during a contrast enhanced ultrasound imaging. The liquid product is composed of lipid-coated, octa-fluoro propane gas-filled echogenic microbubbles. DEFINITY enhances clinicians’ view of the left ventricle of the heart to aid diagnosis during an echocardiogram.

Report Synopsis

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.